{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-342695","form_type":"8-K","ticker":"COGT","cik":"0001622229","company_name":"Cogent Biosciences, Inc.","filed_at":"2026-08-10T21:19:34+00:00","discovered_at":"2026-08-10T21:22:01.656066+00:00","generated_at":"2026-08-10T21:22:08.842055+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cogent Biosciences launches $400M at-the-market equity offering via Guggenheim","bullets":["Filed prospectus supplement on Aug 10, 2026 to sell up to $400M of common stock under ATM sales agreement with Guggenheim Securities.","Offering uses automatic shelf registration on Form S-3ASR filed Nov 7, 2025; shares sold at market prices.","Gibson, Dunn & Crutcher issued legal opinion on the shares, filed as exhibit to this 8-K."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-342695","json":"https://secwatch.observer/filing/0001193125-26-342695.json","markdown":"https://secwatch.observer/filing/0001193125-26-342695.md","text":"https://secwatch.observer/filing/0001193125-26-342695.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1622229/000119312526342695/0001193125-26-342695-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1622229/000119312526342695/d132277d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-10T21:22:08.842055+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}